Shikha Sharma

Nanoparticles  act  as  a  promising  system  for  targeted  delivery  of  drugs  and  as  an  effective  route  of  drug  administration.  In  this  study,  polysorbate  80  coated  nanoparticles  of  serratiopeptidase  were  formulated  and  aimed for  the  treatment  of  blood  clots  in  brain.  Serratiopeptidase exerts effective activity against blood clotting and has ability to dissolve non-living tissues,   blood clots, cysts, atherosclerotic clots. Different  nanoparticle  formulations  of  serratiopeptidase  were  prepared  with  different  concentrations  of  chitosan  and  tripolyphosphate  using  ionic  gelation  method.  The  nanoparticles were coated using polysorbate 80 and were characterized  and  evaluated  for  different  parameters  such  as  particle  size,  entrapment  efficiency,  zeta  potential and  transmission  electron  microscopy.  The  in  vitro  drug  release  of  prepared  nanoparticles  was  studied  in  phosphate  buffer  (pH 7.4).  The  results  indicated  that  the  developed  nanoparticle  formulation  could  be  established  as  a  promising carrier  for  active  targeting  into  brain  to  dissolve  blood  clots.

Desloratadine is an antagonist at histamine H1 receptors, and an antagonist at all subtypes of the muscarinic acetylcholine receptor. It has a long-lasting effect and in moderate and low doses, does not cause drowsiness because it does not readily enter the central nervous system. The present study is an attempt to formulate and evaluate the fast dissolving tablets of  Desloratadine. Fast dissolving tablets were prepared by direct compression after masking the bitter taste of drug by solid dispersion method with the aid of superdisintegrants. Seven formulations were developed using two different superdisintegrants in varying concentrations in such a way that total weight of the tablet remains the same. The drug-polymer incompatibility was ruled out by FTIR studies. All the formulated tablets were subjected for pre and post-compression evaluation parameters. A comparison of in vitro drug release of best formulation along with F1 formulation having no superdisintegrants is carried out. All the formulated tablets were shown satisfactory results which complies with official limits. Among the seven formulations, F7 was selected as the best formulation as its wetting time was 33 seconds, disintegration time was 29 seconds and %CDR after 8 minutes was 100.1%. F7 was found to be stable at 25°C ± 2 °C,  60°C ± 5°C and 40 °C ± 2 °C and 75 ± 5 % RH . Formulated tablets containing high concentration of croscarmellose sodium are better and effective than conventional tablets to meet patient compliance, give fast relief from allergy and cost effective.